Literature DB >> 2838179

Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.

M S Reitz1, C Wilson, C Naugle, R C Gallo, M Robert-Guroff.   

Abstract

Transmission and growth of HIV-1 produced from the biologically active clone HTLV-III/HXB2D in the constant presence of a neutralizing antiserum yielded a viral population specifically resistant to neutralization by the same antiserum. Molecular clones MX-1 and -2, containing the entire envelope gene, were obtained from cultures of the resistant variant. The coding regions for the large envelope protein and most of the transmembrane envelope protein of two such clones were substituted for the homologous segment of HXB2D. Infectious viruses from these constructs were also specifically resistant to neutralization by the selecting antiserum. The exchanged fragment contained only one base change, resulting in an Ala----Thr replacement at position 582. When this substitution was introduced into HXB2D it conferred the resistant phenotype. Thus, small differences may be selected for in vivo by the host immune response and result in relatively large differences in susceptibility of the virus to such a response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838179     DOI: 10.1016/0092-8674(88)90179-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  69 in total

1.  Substitutions in the receptor-binding domain of the avian sarcoma and leukosis virus envelope uncouple receptor-triggered structural rearrangements in the surface and transmembrane subunits.

Authors:  R Damico; L Rong; P Bates
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Dynamic copy choice: steady state between murine leukemia virus polymerase and polymerase-dependent RNase H activity determines frequency of in vivo template switching.

Authors:  C K Hwang; E S Svarovskaia; V K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

3.  Duck hepatitis B virus can tolerate insertion, deletion, and partial frameshift mutation in the distal pre-S region.

Authors:  J S Li; L Cova; R Buckland; V Lambert; G Deléage; C Trépo
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

4.  Direct determination of the point mutation rate of a murine retrovirus.

Authors:  R J Monk; F G Malik; D Stokesberry; L H Evans
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

5.  Alternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.

Authors:  Kieran Cashin; Michael Roche; Jasminka Sterjovski; Anne Ellett; Lachlan R Gray; Anthony L Cunningham; Paul A Ramsland; Melissa J Churchill; Paul R Gorry
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

6.  Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.

Authors:  B Labrosse; O Pleskoff; N Sol; C Jones; Y Hénin; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

7.  Characterization and large production of human monoclonal antibodies against the HIV-1 envelope.

Authors:  V Boyer; H Broly; S Souche; P Madaule; J Rossier; D Zagury; C Desgranges
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

8.  Homogenous HIV-1 subtype B quasispecies in Brazilian men and women recently infected via heterosexual transmission.

Authors:  Nancy Lima Gouveia; Michelle Camargo; Marcos Montani Caseiro; Luiz Mario Ramos Janini; Maria Cecilia Araripe Sucupira; Ricardo Sobhie Diaz
Journal:  Virus Genes       Date:  2014-02-14       Impact factor: 2.332

9.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

Authors:  C Wilson; M S Reitz; K Aldrich; P J Klasse; J Blomberg; R C Gallo; M Robert-Guroff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

10.  Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.

Authors:  R J Grimaila; B A Fuller; P D Rennert; M B Nelson; M L Hammarskjöld; B Potts; M Murray; S D Putney; G Gray
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.